Journals / Tüberküloz ve Toraks / 2019 / Cilt: 67 - Sayı: 3

The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma

Malign mezotelyomada bazı klinikopatolojik parametrelerin ve gen protein ekspresyonlarının prognostik analizi

Pages
162–168
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The primary end point of this study was to invastigate the relationshipof progression free survival (PFS) and overall survival (OS) with the c-Met,EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels in thetumour tissue of pleural and peritoneal mesothelioma cases.Materials and Methods: The study included 53 patients diagnosed withmesothelioma between 2005 and 2016.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Mesothelioma is an aggressive tumour that originates in seroussurfaces.
📊
Key Findings & Data:The primary end point of this study was to invastigate the relationshipof progression free survival (PFS) and overall survival (OS) with the c-Met,EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels in thetumour tissue of pleural and peritoneal mesothelioma cases.Materials and Methods: The study included 53 patients diagnosed withmesothelioma between 2005 and 2016.
💡
Conclusion & Impact:Accordingto the PDGFR expression, OS and PFS of the pleural cases with low expression(0, 1+) was seen to be significantly better than that of the pleural cases withhigh expression (2+, 3+) (p< 0.05).Conclusion: The examination of c-MET, PDGFR-alpha and m-TOR expressionin the in the tumor tissue of mesothelioma cases may be important indetermining prognosis.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Mesothelioma is an aggressive tumour that originates in seroussurfaces. The primary end point of this study was to invastigate the relationshipof progression free survival (PFS) and overall survival (OS) with the c-Met,EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels in thetumour tissue of pleural and peritoneal mesothelioma cases.Materials and Methods: The study included 53 patients diagnosed withmesothelioma between 2005 and 2016. The cases were separated into 2groups as pleural and peritoneal. The effects on OS and PFS were examinedof the c-Met, EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expressionlevels and also clinicopathological parameters and the treatments given. In thestatistical analysis of the data obtained, IBM SPSS vn 20.0 software was used.Results: Of the 53 patients included in the study, 39 (73.6%) were diagnosedwith pleural mesothelioma and 14 (26.4%) with peritoneal mesothelioma.According to the c-Met and mTOR expression, OS and PFS of the peritonealcases with high expression (2+, 3+) was seen to be significantly better thanthat of the peritoneal cases with low expression (0, 1+) (p< 0.05). Accordingto the PDGFR expression, OS and PFS of the pleural cases with low expression(0, 1+) was seen to be significantly better than that of the pleural cases withhigh expression (2+, 3+) (p< 0.05).Conclusion: The examination of c-MET, PDGFR-alpha and m-TOR expressionin the in the tumor tissue of mesothelioma cases may be important indetermining prognosis.

Özet

Giriş: Mezotelyoma, seröz yüzeylerden kaynaklanan agresif seyirli bir tümördür. Bu çalışmanın birincil sonlanım noktası, progresyonsuz sağkalım (PS) ve genel sağkalım (GS) ile plevral ve peritoneal mezotelyoma olgularındaki tümör dokusunda c-Met, EGFR, PTEN, PDGFR-alfa, PI3K/AKT ve mTOR ekspresyon düzeylerinin ilişkisini incelemekti. Materyal ve Metod: Çalışmaya 2005-2016 yılları arasında mezotelyoma tanısı konan 53 hasta dahil edildi. Olgular plevral ve peritoneal olmak üzere iki gruba ayrıldı. GS ve PS üzerindeki etkiler c-Met, EGFR, PTEN, PDGFR-alfa, PI3K/AKT ve mTOR ekspresyon düzeyleri ile klinikopatolojik parametreler ve verilen tedaviler açısından incelendi. Elde edilen verilerin istatistiksel analizinde IBM SPSS vn 20.0 yazılımı kullanıldı. Bulgular: Çalışmaya dahil edilen 53 hastadan 39 (%73.6)’una plevral mezotelyoma, 14 (%26.4)’üne peritoneal mezotelyoma tanısı kondu. c-Met ve mTOR ekspresyonuna göre; yüksek eksprese olan (2+, 3+) peritoneal olguların GS ve PS oranlarının, düşük eksprese (0, 1+) olan peritoneal olgulardan anlamlı olarak daha iyi olduğu görüldü (p< 0.05). PDGFR ekspresyonuna göre; düşük eksprese olan (0, 1+) plevral olguların GS ve PS oranlarının, yüksek eksprese olan (2+, 3+) plevral olgulardan anlamlı olarak daha iyi olduğu görüldü (p< 0.05). Sonuç: Mezotelyoma olgularının biyopsi ve operasyon materyallerinde c-Met, PDGFR-alfa ve mTOR ekspresyonunun incelenmesi prognozun belirlenmesinde önemli olabilir.

🔖

Cite This Article

GÜMÜRDÜLÜ, D., BAĞIR, E., TOHUMCUOĞLU, M., BÜYÜKŞİMŞEK, M., KARA, İ. O. (2022). The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma. Tüberküloz ve Toraks, Cilt: 67 - Sayı: 3, 162–168. https://ajindex.com/articles/618396

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Tischoff I, Tannapfel A. Mesothelioma. Pathologe 2017;38:547-60
  2. Lemen RA. Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States. J Toxicol Environ Health B Crit Rev 2016;19:250-65
  3. Mensi C, Mendola M, Dallari B, Sokooti M, Tabibi R, Riboldi L, et al. Differences between peritoneal and pleural mesothelioma in Lombardy, Italy. Cancer Epidemiol 2017;51:68-73
  4. Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, et al. c-Met expression and MET amplification in malignant pleural mesothelioma. Ann Diagn Pathol 2016;23:1-7
  5. Liang Y, Zheng G, Yin W, Song H, Li C, Tian L, et al. Significance of EGFR and PTEN expression and PLR and NLR for predicting the prognosis of epithelioid malignant peritoneal mesothelioma. Gastroenterol Res Pract 2019;2019:7103915
  6. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 2017;17:475-88
  7. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008;33:502-6
  8. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, Gerwin BI. Paradoxical effects of plateletderived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 2001;24:694-702
  9. Ramos-Nino ME, Vianale G, Sabo-Attwood T, Mutti L, Porta C, Heintz N, et al. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 2005;4:835-42
  10. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, et al. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 2011;179:1483-93
  11. Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, et al. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer 2016;96:1-6
  12. Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, Brochard P, Astoul P, et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignantmesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol 2012;7:599-606
  13. Dziadziuszko R, Wynes MW, Singh S, Asun